PHARMACIE NGUYEN : revenue, balance sheet and financial ratios

PHARMACIE NGUYEN is a French company founded 6 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in ROISSY-EN-BRIE (77680), this company of category PME shows in 2021 a revenue of 596 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-04-18

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - PHARMACIE NGUYEN (SIREN 880849708)
Indicator 2024 2023 2021 2020
Revenue N/C N/C 596 172 € 94 328 €
Net income 13 507 € 27 050 € -19 012 € -55 279 €
EBITDA N/C N/C 39 656 € -33 781 €
Net margin N/C N/C -3.2% -58.6%

Revenue and income statement

In 2024, PHARMACIE NGUYEN generates positive net income of 14 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax.

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

13 507 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 2650%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 3%. Low autonomy: the company heavily depends on external financing (banks, suppliers).

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

2650.2%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

2.542%

Asset age ratio (2024) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

57.1%

Solvency indicators evolution
PHARMACIE NGUYEN

Sector positioning

Debt ratio
2650.2 2024
2021
2023
2024
Q1: 16.45
Med: 58.41
Q3: 154.59
Average +50 pts over 3 years

In 2024, the debt ratio of PHARMACIE NGUYEN (2650.20) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
2.54% 2024
2021
2023
2024
Q1: 28.92%
Med: 49.95%
Q3: 69.49%
Watch

In 2024, the financial autonomy of PHARMACIE NGUYEN (2.5%) ranks in the bottom 25% of the sector. This ratio represents the share of equity in total financing. Low autonomy may limit investment capacity and increase vulnerability.

Repayment capacity
28.92 years 2021
2021
Q1: 1.06 years
Med: 3.56 years
Q3: 7.31 years
Average

In 2021, the repayment capacity of PHARMACIE NGUYEN (28.92) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 119.34. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

119.336

Liquidity indicators evolution
PHARMACIE NGUYEN

Sector positioning

Liquidity ratio
119.34 2024
2021
2023
2024
Q1: 129.47
Med: 182.14
Q3: 260.79
Watch +7 pts over 3 years

In 2024, the liquidity ratio of PHARMACIE NGUYEN (119.34) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.

Interest coverage
30.31x 2021
2021
Q1: 0.27x
Med: 2.43x
Q3: 5.92x
Excellent

In 2021, the interest coverage of PHARMACIE NGUYEN (30.3x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
PHARMACIE NGUYEN

Positioning of PHARMACIE NGUYEN in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 225 transactions of similar company sales in 2024, the value of PHARMACIE NGUYEN is estimated at 188 567 € (range 131 315€ - 282 108€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2024
225 transactions
131k€ 188k€ 282k€
188 567 € Range: 131 315€ - 282 108€
NAF 5 année 2024

Valuation method used

Net Income Multiple
13 507 € × 14.0x = 188 568 €
Range: 131 316€ - 282 108€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare PHARMACIE NGUYEN with other companies in the same sector:

Frequently asked questions about PHARMACIE NGUYEN

What is the revenue of PHARMACIE NGUYEN ?

The revenue of PHARMACIE NGUYEN in 2021 is 596 k€.

Is PHARMACIE NGUYEN profitable?

Yes, PHARMACIE NGUYEN generated a net profit of 14 k€ in 2024.

Where is the headquarters of PHARMACIE NGUYEN ?

The headquarters of PHARMACIE NGUYEN is located in ROISSY-EN-BRIE (77680), in the department Seine-et-Marne.

Where to find the tax return of PHARMACIE NGUYEN ?

The tax return of PHARMACIE NGUYEN is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does PHARMACIE NGUYEN operate?

PHARMACIE NGUYEN operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.